Department of Psychiatry
Penn Behavioral Health

HIV/AIDS Prevention Research Division

subpage feature

Recent Publications


Eisenberg, M.M. & Blank, M.B. (2004). HIV and serious mental illness: Prevalence and treatment issues. Harvard Health Policy Review, 5 (2), 48-54.

Blank, M. and Eisenberg, M. (Editors). (2007). HIV: Issues with mental health and illness. Journal of Prevention and Intervention in the Community. 33 (#1 & 2).

Kraut-Becher JR, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral SO. Examining Racial Disparities in HIV: Lessons from Sexually Transmitted Infections Research. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2008; 47 Supplement 1:S20-S27.

Kraut-Becher JR, Aral SO. Age Mixing Patterns and Sexually Transmitted Infections. Intl Jrl STD & AIDS. 2006; 17:378-383.

Davis C, Burris S, Kraut-Becher JR, Lynch K, Metzger DS. Effects of an Intensive Street-Level Police Intervention on Syringe Exchange Program Utilization: Philadelphia, PA. The American Journal of Public Health 2005; 95:233-236.

Kraut-Becher JR, Gift T, Haddix A, Irwin K, Greifinger R. The Cost-Effectiveness of Universal Screening for Chlamydia and Gonorrhea in United States Jails. Journal of Urban Health 2004; 81: 453-471.

Kraut JR, Aral SO. Gap Length: An Important Factor in Sexually Transmitted Diseases Transmission. Sexually Transmitted Diseases 2003; 30(30): 221-225.

Kraut JR, Haddix AC, Carande-Kulis V, Greifinger RB. The Cost-Effectiveness of Routine Screening for Sexually Transmitted Diseases in United States Prisons and Jails. In: The Health Status of Soon-to-Be-Released Inmates: A Report to Congress. National Commission on Correctional Health Care, Chicago, IL, 2002.

Kraut JR, Beidinger H, McIntyre A, Mier S, Beete D, Broussard D, Irwin K. Costs of Syphilis Screening at a Chicago Jail, USA. International Journal of STD & AIDS 2001, 12(Suppl 2):169.

Kraut JR, Aral SO. Patterns of Age Mixing are Associated with STDs in the USA. International Journal of STD & AIDS 2001, 12(Suppl 2):188.

Mayer KH, Maslankowski L, Gai F, El-Sadr W, Justman J, Kwiecien A, Mâsse B, Eshleman SH7, Hendrix C, Morrow K, Rooney JF, Lydia Soto-Torres L, and the HPTN 050 Protocol Team. Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-uninfected and infected women. AIDS. 2006, 20:543-551.

El-Sadr W, Mayer KH, Maslankowski L, Hoesley, C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006, 20:1109-1116.

Rosen, R, Morrow, K, Carballo-Dieguez, A, Mantell, J, Hoffman, S, Gai, F, Maslankowski, L, El- Sadr, W, Mayer, K. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed methods study. Journal of Women’s Health. 008.

Carballo-Dieguez A, Balan, Morrow K, Rosen R, Mantell, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K. Acceptability of tenofovir gel as a vaginal microbicide by U.S. male participants in a phase I clinical trial (HPTN 050). AIDS Care. 2007.

Joshi S, Dutta S, Bell B, Profy A, Kuruc J, Fang G, Cianciola M, Maslankowski L, Soto-Torres L, Panchanadikar A, Mehendale S, Reynolds SJ. Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned. AIDS Res Hum Retroviruses. 2006; 22:294-6.

Njoroge B, Chirenje ZM, Bina P, Florence M, Joshi S, Low-Beer N, Maslankowski L. The CONRAD/WHO Update 2000 Colposcopy Manual: how well is it working? J AIDS 2004, 35 (Supplement 2).

Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z for the HIV Prevention Trials Network (HPTN) 020 Protocol Team. Safety and tolerability of vaginal Pro 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003; 17:321-29.

Morrow, K, Rosen, R, Richter, L, Emans, A, Forbes, A, Day J, Morar, N, Maslankowski L, Profy AT, Cliff, K, Karim SA, Mayer KH. The acceptability of an investigational vaginal microbicide, PRO2000 Gel, among women in a Phase I clinical trial. Journal of Women’s Health, 2003, 12, 7:655-66.

Mayer KH, Kelly C, Morar NS, Maslankowski. L, Emans A, Welch J. The Safety and tolerability of PRO2000 Gel, a novel vaginal microbicide, in sexually active HIV- and abstinent HIV+ women (HIVNET 020). Int J STDs & AIDS 2001; 12 (suppl 2):35.

Metzger DS, Woody GE, DePhilippis D, McLellan AT, O'Brien CP, Platt JJ (1991) Risk factors for needle sharing among methadone patients. American Journal of Psychiatry, 1991; 148(5):636-640.

Watkins K, Metzger D., Woody, G, McLellan, A. T. High-risk sexual behaviors of intravenous drug users in-and out-of-treatment: implications for the spread of HIV infection. American Journal of Drug and Alcohol Abuse, 1992; 18(4): 389-398.

McLellan, A.T., Arndt, I.O., Metzger, D., Woody, G.E., O'Brien, C.P. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 1993; 296: 1953-1959.

Watkins, K., Metzger, D., Woody, G., McLellan, A.T. Determinants of condom use among intravenous drug users. AIDS, 1993; 7: 719-723.

Metzger, D.S., Woody, G., McLellan, A.T., O'Brien, C.P., Druley, P., Navaline, H., DePhilippis, D., Stolley, P., Abrutyn, E. Human immunodeficiency virus seroconversion among in- and out-of-treatment intravenous drug users: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 1993; 6:1049-1056.

Woody, G. and Metzger, D.S. (1993) Letter: Causes of death in injection-drug users. New England Journal of Medicine, 1993; 329: 1661.

Navaline, H., Snider, E., Petro, C., Tobin, D., Metzger, D., Alterman, A., Woody, G. (1994). Automated version of the Risk Assessment Battery (RAB): Enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses; 10(S2):S281-S283.

Cohen, E., Navaline, H. and Metzger, D. High Risk Behaviors for HIV: A comparison between crack-abusing and opioid-abusing African-American women. Journal of Psychoactive Drugs, 1995; 26: 233-241.

McLellan, A.T., Woody, G.E., and Metzger, D.S. Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. The Milbank Quarterly, 1996; 74: 51-86.

Metzger, D.S., Navaline, H.A., Woody, G.E. Drug abuse treatment as AIDS prevention. Public Health Reports, 1998; 113: 97-106.

Metzger, D.S., Navaline, H.A. and Woody, G.E. The role of drug treatment in the prevention of HIV infection. In Peterson, JL and DiClemente, RJ (Eds.), Handbook of HIV Prevention. Plenum Publishing Corporation, New York, 2000.

Metzger, D.S., Koblin, B., Turner, C.F., Navaline, H., Valente, F., Holte, S., Gross, M., Sheon, A., Miller, H., Seage, G. for the HIVNET VPS protocol team. A randomized controlled trial of audio-assisted computer self-interviewing: impact, feasibility, and acceptability. American Journal of Epidemiology, 2000; 152 (2): 99-106.

Seage, G.R., Holte, S.E., Metzger, D., Koblin, B.A., Gross, M., Celum, C., Marmor, M., Woody, G., Mayer, K.H., Stevens, C., Judson, F.N., McKirnan, D., Sheon, A., Self, S., Buchbinder, S.P. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. American Journal of Epidemiology, 2001; 173 (7): 619-627.

Strauss RP, Sengupta S, Kegeles S, McLellan E, Metzger D, Eyre S, Khanani F, Emrick CB, MacQueen KM. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. Journal of Acquired Immune Deficiency Syndromes, 2001; 26(1):63-71.

Halpern, S., Metzger, D., Berlin, J., Ubel, P. Who Will Enroll? Predicting participation in a Phase II AIDS vaccine trial. Journal of Acquired Immune Deficiency Syndromes, 2001; 27: 281-288.

MacQueen, K.M., McLellan, E., Metzger, D.S., Kegeles, S., Strauss, R.P., Scotti, R., Blanchard, L., Trotter, R.T. What is community? An evidence based definition for participatory public health. American Journal of Public Health, 2001, 91:12: 1929-1938

Wang X., Douglas, S.D., Metzger, D.S., Guo, C-J, Li, Y., O’Brien, C.P., Song, L. Davis-Vogel, A. and Ho, W-Z. Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin. Exp. Res. 26:1880-1886, 2002.

Coletti, A., Heagerty, P., Sheon, A., Gross, M., Koblin, B., Metzger, D., Seage, G. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine trials. Journal of Acquired Immune Deficiency Syndromes, 2003; 32: 161-169.

Pechansky, F., von Diemen, L., Kessler, F., Hirakata, V., Metzger, D. and Woody, G. Prelimimnary estimates of human immunodeficiency virus prevalence and incidence among cocaine abusers of Porto Alegre, Brazil. Journal of Urban Health, 2003; 80 (1): 115-126.

Messiah, A., Navaline, H., Davis-Vogel, A., Tobin-Fiore, D., Metzger, D. Sociodemographic and behavioral characteristics associated with timeliness and retention in a six-month follow-up study of high-risk injection drug users. American Journal of Epidemiology, 2003, 157: 930-939.

Metzger, D.S., Navaline, H.A. HIV prevention among injection drug users: the need for integrated models. Journal of Urban Health, 2003, 80:4(Suppl 3): 59-64.

Metzger, D.S., Navaline, H.A. Human immunodeficiency virus prevention and the potential of drug abuse treatment. Clinical Infectious Diseases, 2003, 37(Suppl 5): S451-S456.

Needle, R.H., Trotter, R.T. II, Singer, M., Bates, C., Page, J.B., Metzger, D., Marcelin, L. Rapid Assessment of HIV/AIDS crisis in racial and ethnic minority communities: approach for timely community interventions. Am J Pub Health, 2003, 93: 970-979.

Li, Y., Merrill, J.D., Mooney, K., Song, L., Wang, X, Guo, C-J, Savani, R.C., Metzger, D.S., Douglas, S.D. and Ho, W-Z. Morphine enhances HIV infection of neonatal macrophages. Pediatr. Res. 54:282-288, 2003.

Metraux, S., Metzger, D., and Culhane, D. Homelessness and HIV risk behaviors among injection drug users. Journal of Urban Health, 2004, 81(4), 618-629.

Davis, C., Burris, S., Lynch, K., Becher, J., Metzger, D. Effects of an intensive street-level police intervention on syringe exchange program utilization: Philadelphia, PA. American Journal of Public Health, 2005, 95 (2), 233-236.

Sullivan, L., Metzger, D.S., Fudala, P.J., Fiellin, D.A. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction, 2005, 100; 150-158.

Li, Y., Wang, X., Douglas, S.D., Metzger, D.S., Woody, G., Zhang, T., Song, L., Ho, W-Z.: CD8+ T cell depletion amplifies hepatitis C virus replication in peripheral blood mononuclear cells. J. Infect. Dis. 192:1093-1101, 2005.

Zhang, T., Guo, C-J., Douglas, S.D., Metzger, D.S., O’Brien, C.P., Li, Y., Wang, Y-J., Wang, X., and Ho, W-Z.: Alcohol suppresses IL-2-induced CC-chemokine production by natural killer cells. Alcohol. Clin. Exp. Res. 2:1559-1567, 2005.

Wang, C-Q., Li, Y., Douglas, S.D., Wang, X., Metzger, D.S., Zhang, T., and Ho, W-Z.: Morphine withdrawal enhances hepatitis C virus replicon expression. Am. J. Pathol. 167: 1333-1340, 2005.

Azevedo-Simoes, A., Bastos, C.I., Moreira, R.I., Lynch, K., Metzger, D.S. Acceptability of audio-assisted self-interview (ACASI) among substance abusers seeking treatment in Rio de Janeiro, Brazil. Drug and Alcohol Dependence 82 Suppl. 1 (2006) S103-S107.

Mark HD, Nanda J, Davis-Vogel A, Navaline H, Scotti R, Wickrema R, Metzger D, Sochalski J. Profiles of Self-Reported HIV-Risk Behaviors Among Injection Drug Users in Methadone Maintenance Treatment, Detoxification, and Needle Exchange Programs. Public Health Nursing. 2006 Jan-Feb; 23(1):11-9.

Wang X, Douglas SD, Peng JS, Metzger DS, O’Brien CP, Zhang T, Ho W. Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. Journal Leukocyte Biology. 79, 1166-1172, 2006.

Plotzker, RE; Metzger, DS; Holmes, WC.Childhood sexual and physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: a potential mediating pathway. AmJAdd 16431-438 2007

Blank, MB; Metzger, DS; Wingood, GM; DiClemente, RJ. First national scientific meeting of the social and behavioral science research network. JAIDS 47S1-S4 2008.

DiClemente, RJ; Wingood, GM; Blank, MB; Metzger, DS. Future directions for HIV prevention research - charting a prevention science research agenda. JAIDS 47S47-S48 2008.

 

Connect with us twitter

Contact Us arrow

To make an appointment, or inquire further about our services, please call: 1-866-448-7366.

Click here for directions and contact information.